Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Mesial Temporal Lobe Epilepsy: full-pipeline trial registry
3 of 3 indexed Mesial Temporal Lobe Epilepsy trials are currently recruiting.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Mesial Temporal Lobe Epilepsy: 3 US clinical trials tracked, 3 recruiting.
Mesial Temporal Lobe Epilepsy is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is UniQure Biopharma B.V., running 1 of these trials.
Enrollment posture brief
Registry condition mesial-temporal-lobe-epilepsy
OPEN 3 | RECR 100% | LATE 1 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Mesial Temporal Lobe Epilepsy lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Mesial Temporal Lobe Epilepsy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Mesial Temporal Lobe Epilepsy is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
Neurona Therapeutics
NCT05135091
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
UniQure Biopharma B.V.
NCT06063850
PRIME: PReservIng Memory in Epilepsy
Nitin Tandon
NCT05608408
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Mesial Temporal Lobe Epilepsy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Mesial Temporal Lobe Epilepsy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Mesial Temporal Lobe Epilepsy page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Mesial Temporal Lobe Epilepsy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- UniQure Biopharma B.V. sponsors the most Mesial Temporal Lobe Epilepsy trials on record, review their full trial history before evaluating a specific study. See UniQure Biopharma B.V.'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mesial Temporal Lobe Epilepsy condition card totals 3 registered trials; most-linked intervention AAV9-hSyn1-miGRIK2; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.